Goodwin Procter Advised Banks On €13 Million Public Equity Investment In MaaT Pharma

Goodwin Procter Advised Banks On €13 Million Public Equity Investment In MaaT Pharma

The fundraising will support its progress towards key value milestones

American multinational law firm Goodwin Procter has advised Van Lanschot Kempen N.V., Chardan and KBC Securities on the capital increase of MaaT Pharma for €13 million through a private placement.

MaaT Pharma is a leading late-stage clinical company. It develops innovative gut microbiome-driven therapies to modulate the immune system and enhance the survival rate of cancer patients.

The fundraising will support market submission for European Union approval of MaaT013.

The Goodwin Procter capital markets team was led by Partner Guilhem Richard on French laws and Partner and Co-Chair Edwin O’Connor on US laws. The team included Counsel Mariléna Gryparis and Associate Shanna Kim.

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.